Six cycles of docetaxel and cyclophosphamide have been shown to be noninferior to EC-T in HER2-negative early breast cancer, supporting docetaxel and cyclophosphamide as a viable anthracycline-free option (Nitz et al., 2019). The gene discussed is ERBB2; the disease is breast carcinoma.